Johnson & Johnson's Janssen Pharmaceutical unit has a long heritage and established commercial position in multiple myeloma – where the company is now trying to develop curative regimens – but the firm is also working to expand more broadly in solid tumor indications, including non-small cell lung cancer, bladder cancer and earlier-stage prostate cancer.
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's broad oncology strategy ahead of a...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

